References
1. Denning DW, Pleuvry A, Cole DC. Global burden of allergic
bronchopulmonary aspergillosis with asthma and its complication chronic
pulmonary aspergillosis in adults. Med Mycol2013;51(4) :361-370.
2. Vitte J, Michel M, Malinovschi A, Caminati M, Odebode A,
Annesi-Maesano I, et al., Fungal exposome, human health and unmet needs:
a 2022 update with special focus on allergy. Allergy 2022;in
press.
3. Denning DW, O’Driscoll BR, Hogaboam CM, Bowyer P, Niven RM. The link
between fungi and severe asthma: a summary of the evidence. Eur
Resp J 2006;27 :615-26.
4. Le Cann P, Paulus H, Glorennec P, Le Bot B, Frain S, Gangneux JP.
Home environmental interventions for the prevention or control of
allergic and respiratory diseases: What Really Works. J Allergy
Clin Immun Pract 2017;5 :66-79.
5. Anderson HM, Jackson DJ. Microbes, allergic sensitization, and the
natural history of asthma. Curr Opin Allergy Clin Immunol2017;17 :116–122.
6. Gangneux JP, Bouvrais M, Frain S, Morel H, Deguen S, Chevrier S, Le
Cann P. Asthma and Indoor Environment: Usefulness of a Global Allergen
Avoidance Method on Asthma Control and Exposure to Molds.Mycopathologia 2020;185(2) :367-371.
7. Ram B, Aggarwal AN, Dhooria S, Sehgal IS, Garg M, Behera D, et al. A
pilot randomized trial of nebulized amphotericin in patients with
allergic bronchopulmonary aspergillosis. J Asthma2016;53(5) :517-24.
8. Godet C, Couturaud F, Marchand-Adam S, Pison C, Gagnadoux F,
Blanchard E, et al.; NebuLamB* study group and GREPI network. Nebulised
liposomal-amphotericin-B as maintenance therapy in ABPA: a randomised,
multicentre, trial. Eur Respir J 2021;2102218.
9. Agache I, Rocha C, Beltran J, Song Y, Posso M, Solà I, et al.
Efficacy and safety of treatment with biologicals (benralizumab,
dupilumab and omalizumab) for severe allergic asthma: A systematic
review for the EAACI Guidelines - recommendations on the use of
biologicals in severe asthma. Allergy2020;75(5) :1043-1057.